Solid Biosciences Inc (SLDB)

$6.90 -0.33 (-4.56%)
Market Cap 711.53M
Revenue (ttm) 0.00
Net Income (ttm) -174.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,422,200
Avg Vol 1,292,190
Day's Range N/A - N/A
Shares Out 98.41M
Stochastic %K 8%
Beta 2.47
Analysts Strong Sell
Price Target $17.08

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
pharmd2828
pharmd2828 May. 5 at 8:07 PM
$SLDB whales staying on board heavily!
0 · Reply
diggs24
diggs24 May. 5 at 5:36 PM
$SLDB Added 650@$6.80
0 · Reply
Michael1965now
Michael1965now May. 4 at 2:24 PM
$SLDB It is pretty obvious....but people are still just people....
0 · Reply
Robby83
Robby83 May. 4 at 2:19 PM
$SLDB not much of a retracement... looks a little premature to continue on but hey, not complaining.
0 · Reply
ChubbyDave
ChubbyDave May. 3 at 9:32 PM
$SLDB waiting for retrace to around 6.50 this week to reload…burn baby burn
0 · Reply
NeverPop
NeverPop May. 2 at 7:11 PM
$SLDB what is the odds they get accelerated approval?
3 · Reply
pharmd2828
pharmd2828 Apr. 30 at 9:10 PM
$SLDB in full force moving forward!!
0 · Reply
Jonrenie
Jonrenie Apr. 29 at 6:47 PM
$SLDB load up y'all
1 · Reply
pharmd2828
pharmd2828 Apr. 28 at 6:46 PM
$SLDB per PR from today; phase 3 has started .. is this correct ???
0 · Reply
DARKP00L
DARKP00L Apr. 28 at 12:08 PM
$SLDB 08:02 on Apr. 28 2026 Solid Biosciences Says European Commission Grants Orphan Drug Designation To SGT-003 For Treatment Of Duchenne Muscular Dystrophy #tradeideas
0 · Reply
Latest News on SLDB
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 4:05 PM EDT - 4 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Apr 30, 2026, 8:00 AM EDT - 5 days ago

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Apr 28, 2026, 8:00 AM EDT - 7 days ago

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 2:15 PM EDT - 21 days ago

Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Solid Biosciences to Participate at Upcoming Investor Conferences

Apr 7, 2026, 8:00 AM EDT - 4 weeks ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 19, 2026, 4:12 PM EDT - 6 weeks ago

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 11:30 AM EDT - 7 weeks ago

Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Mar 11, 2026, 3:14 PM EDT - 7 weeks ago

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

Mar 11, 2026, 1:01 PM EDT - 7 weeks ago

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Mar 6, 2026, 8:31 AM EST - 2 months ago

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 6, 2026, 8:30 AM EST - 2 months ago

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 10:30 AM EST - 2 months ago

Solid Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

Feb 9, 2026, 8:00 AM EST - 3 months ago

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 6, 2026, 8:00 AM EST - 3 months ago

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Solid Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 4 months ago

Solid Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Jan 13, 2026, 4:15 PM EST - 4 months ago

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Jan 12, 2026, 4:15 PM EST - 4 months ago

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Jan 12, 2026, 8:05 AM EST - 4 months ago

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 4 months ago

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Dec 16, 2025, 4:51 PM EST - 5 months ago

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Dec 8, 2025, 8:00 AM EST - 5 months ago

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Solid Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 11:30 AM EST - 5 months ago

Solid Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Dec 1, 2025, 8:00 AM EST - 5 months ago

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Nov 17, 2025, 8:00 AM EST - 6 months ago

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Nov 6, 2025, 8:00 AM EST - 6 months ago

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Nov 3, 2025, 4:05 PM EST - 6 months ago

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Solid Biosciences to Present at Upcoming Scientific Meetings

Oct 1, 2025, 8:00 AM EDT - 7 months ago

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Sep 25, 2025, 8:00 AM EDT - 7 months ago

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Sep 23, 2025, 8:00 AM EDT - 8 months ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Sep 23, 2025, 8:00 AM EDT - 8 months ago

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Solid Biosciences Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 3:10 PM EDT - 8 months ago

Solid Biosciences Transcript: Baird Global Healthcare Conference 2025

Solid Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:00 AM EDT - 8 months ago

Solid Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Solid Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:20 PM EDT - 8 months ago

Solid Biosciences Transcript: Cantor Global Healthcare Conference 2025

Solid Biosciences Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 1:45 PM EDT - 8 months ago

Solid Biosciences Transcript: Citi's Biopharma Back to School Conference

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 4:07 PM EDT - 9 months ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 10 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 8, 2025, 4:05 PM EDT - 10 months ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 2:00 PM EDT - 11 months ago

Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025, 4:06 PM EDT - 1 year ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 12:30 PM EDT - 1 year ago

Solid Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 2:15 PM EDT - 1 year ago

Solid Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Solid Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Solid Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Solid Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 9:20 AM EDT - 1 year ago

Solid Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 6, 2025, 4:16 PM EST - 1 year ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 12:29 PM EST - 1 year ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Solid Biosciences Transcript: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Transcript: Study Update

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 1 year ago

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025, 6:45 AM EST - 1 year ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 21, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Solid Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 1 year ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Transcript: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Transcript: FDA Announcement

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 1 year ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Dec 13, 2024, 1:52 PM EST - 1 year ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Solid Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 9:30 AM EST - 1 year ago

Solid Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Solid Biosciences Transcript: Citi's 2024 Global Healthcare Conference

Dec 4, 2024, 1:00 PM EST - 1 year ago

Solid Biosciences Transcript: Citi's 2024 Global Healthcare Conference

Solid Biosciences Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 8:30 AM EST - 1 year ago

Solid Biosciences Transcript: Jefferies London Healthcare Conference 2024

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Transcript: Chardan's 8th Annual Genetic Medicines Conference

Sep 30, 2024, 11:00 AM EDT - 1 year ago

Solid Biosciences Transcript: Chardan's 8th Annual Genetic Medicines Conference

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 9:30 AM EDT - 1 year ago

Solid Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 1 year ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 2 years ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

pharmd2828
pharmd2828 May. 5 at 8:07 PM
$SLDB whales staying on board heavily!
0 · Reply
diggs24
diggs24 May. 5 at 5:36 PM
$SLDB Added 650@$6.80
0 · Reply
Michael1965now
Michael1965now May. 4 at 2:24 PM
$SLDB It is pretty obvious....but people are still just people....
0 · Reply
Robby83
Robby83 May. 4 at 2:19 PM
$SLDB not much of a retracement... looks a little premature to continue on but hey, not complaining.
0 · Reply
ChubbyDave
ChubbyDave May. 3 at 9:32 PM
$SLDB waiting for retrace to around 6.50 this week to reload…burn baby burn
0 · Reply
NeverPop
NeverPop May. 2 at 7:11 PM
$SLDB what is the odds they get accelerated approval?
3 · Reply
pharmd2828
pharmd2828 Apr. 30 at 9:10 PM
$SLDB in full force moving forward!!
0 · Reply
Jonrenie
Jonrenie Apr. 29 at 6:47 PM
$SLDB load up y'all
1 · Reply
pharmd2828
pharmd2828 Apr. 28 at 6:46 PM
$SLDB per PR from today; phase 3 has started .. is this correct ???
0 · Reply
DARKP00L
DARKP00L Apr. 28 at 12:08 PM
$SLDB 08:02 on Apr. 28 2026 Solid Biosciences Says European Commission Grants Orphan Drug Designation To SGT-003 For Treatment Of Duchenne Muscular Dystrophy #tradeideas
0 · Reply
pharmd2828
pharmd2828 Apr. 27 at 8:37 PM
$SLDB wow black rock joined the club too! 4.7m shares!
0 · Reply
pharmd2828
pharmd2828 Apr. 26 at 3:37 PM
$SLDB
0 · Reply
Jonrenie
Jonrenie Apr. 24 at 2:39 PM
$SLDB saw 9.30 on this today
2 · Reply
pharmd2828
pharmd2828 Apr. 22 at 1:22 AM
$SLDB today’s filings show that insiders have acquired a lot of shares!
0 · Reply
flowerchefstocks
flowerchefstocks Apr. 21 at 12:41 AM
$SLDB a lot of great stuff going on but this looks like competition in #DMD. This is an important article for the DMD group. Efficacy better than the Standard of Care and really no side effects. #Capricor should be considered. https://talkmarkets.com/article/capricors-pdufa-on-deramiocel-offers-excellent-risk-reward-for-august-expiration-1776703236
0 · Reply
pharmd2828
pharmd2828 Apr. 19 at 5:38 PM
$SLDB It could be a lifetime opportunity! She looks staged for success! Pipelines are absolutely life changing in an unmet therapeutic options! Plz do DD!
1 · Reply
Michael1965now
Michael1965now Apr. 17 at 2:23 PM
$SLDB Planned first phase 3 dosing announcement will pop the stock up 8% to 15%...When will they announce? that is the question. I am looking at Tuesday or Wednesday next week.
0 · Reply
pharmd2828
pharmd2828 Apr. 17 at 12:59 PM
$SLDB under heavy accumulation and healthy consolidation which is very bullish ! IMHO
0 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:43 AM
$SLDB wasup chuck
0 · Reply
Michael1965now
Michael1965now Apr. 14 at 2:43 PM
$SLDB Short margin premium to borrow is costing more today...short will start covering if it moves over $9 to $9.50 with the most short "pain" at $10.50
0 · Reply
Michael1965now
Michael1965now Apr. 14 at 1:54 PM
$SLDB most likely a short squeeze today....watch for a 1pm to 1:15 pm news release...if no news...then Bo will announce it during his fire side chat today at 2 pm to 2:30 pm...
0 · Reply
topstockalerts
topstockalerts Apr. 14 at 2:04 AM
$SLDB this is starting to look like a trend, not just a bounce
0 · Reply